Department of Persian Medicine, School of Persian Medicine, Tehran University of Medical Sciences, Tehran, Iran.
Department of Traditional Pharmacy, School of Persian Medicine, Tehran University of Medical Sciences, Tehran, Iran.
BMC Res Notes. 2021 Jun 30;14(1):253. doi: 10.1186/s13104-021-05667-9.
Psoriasis is an immune-mediated inflammatory skin disease. It can involve any body skin area, particularly the scalp, lower back, elbows, and knees. There are several topical and systemic therapies for the treatment. Nowadays, herbal medicines are popular treatments for dermatologic conditions. This two-arm parallel, randomized placebo-controlled clinical trial was conducted to examine the hypothesis of the efficacy of Melissa officinalis syrup on patients with mild-to-moderate Plaque psoriasis.
Among 100 patients, 95 participants completed the trial and five of them withdrew. The mean pruritus intensity and PASI scores decreased significantly in the intervention group compared to the placebo group (P < 0.001). The DLQI score in the intervention group increased post-treatment compared to pre-treatment (P = 0.029); however, there was no significant difference between the intervention and control group at the end of the study (0.065).
The trial was registered in the Iranian registry of clinical trials on November 9th, 2019 ( https://www.irct.ir/trial/43434 ; registration number: IRCT20191104045326N1).
银屑病是一种免疫介导的炎症性皮肤病。它可以累及身体任何皮肤部位，特别是头皮、下背部、肘部和膝盖。有几种局部和全身疗法可用于治疗。如今，草药是治疗皮肤病的流行疗法。这项双臂平行、随机安慰剂对照临床试验旨在检验 Melissa officinalis 糖浆对轻度至中度斑块型银屑病患者疗效的假设。
在 100 名患者中，95 名参与者完成了试验，其中 5 名退出。与安慰剂组相比，干预组的瘙痒强度和 PASI 评分明显降低（P<0.001）。与治疗前相比，干预组的 DLQI 评分在治疗后增加（P=0.029）；然而，在研究结束时，干预组和对照组之间没有显著差异（0.065）。
该试验于 2019 年 11 月 9 日在伊朗临床试验注册处注册（https://www.irct.ir/trial/43434；注册号：IRCT20191104045326N1）。
